ARTICLE | Clinical News
LymphoStat-B belimumab: Additional Phase II data
June 16, 2008 7:00 AM UTC
The partners reported data from an open-label extension of a 52-week, double-blind, placebo-controlled Phase II study. After 3 years, the response rate among serologically active patients was 52%, up ...